Company · CIK 2029039
Nasus Pharma Ltd
| CIK | 2029039 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2834 — Pharmaceutical Preparations |
| Incorporated in | L3 |
| Business address | Israel |
| Listed | NSRX (NYSE) |
| First annual or quarterly report | 2026-03-25 |
Offerings
3 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-298693 | 2026-09-01 | 2026-09-18 | 3 | |
| 333-293950 | 2026-03-02 | 2026-08-20 | 4 | |
| 333-288582 | 2025-07-09 | 2025-08-14 | 5 |
Filings
13| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2026-09-18 | 424B5Shelf takedown | 333-298693 | 0001493152-26-043370 |
| 2026-09-11 | EFFECTDeclared effective | 333-298693 | 9999999995-26-002954 |
| 2026-09-01 | F-3Shelf registered | 333-298693 | 0001493152-26-041040 |
| 2026-08-20 | EFFECTDeclared effective | 333-293950 | 9999999995-26-002715 |
| 2026-03-31 | EFFECTDeclared effective | 333-293950 | 9999999995-26-001019 |
| 2026-03-13 | EFFECTDeclared effective | 333-293950 | 9999999995-26-000817 |
| 2026-03-02 | F-1Registration filed | 333-293950 | 0001493152-26-008581 |
| 2025-08-14 | 424B4Final prospectus | 333-288582 | 0001641172-25-023826 |
| 2025-08-12 | EFFECTDeclared effective | 333-288582 | 9999999995-25-002578 |
| 2025-08-07 | F-1/AAmendment | 333-288582 | 0001493152-25-011714 |
| 2025-07-28 | F-1/AAmendment | 333-288582 | 0001493152-25-011444 |
| 2025-07-09 | F-1Registration filed | 333-288582 | 0001641172-25-018388 |
| 2024-08-30 | DRSDraft made public | 377-07416 | 0001493152-24-034512 |